



**HAL**  
open science

## Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy

Feriel Azibani, Astrid Brull, Ludovic Arandel, Maud Beuvin, Isabelle Nelson,  
Arnaud Jollet, Esma Ziat, Bernard Prudhon, Sofia Benkhelifa-Ziyyat, Marc  
Bitoun, et al.

► **To cite this version:**

Feriel Azibani, Astrid Brull, Ludovic Arandel, Maud Beuvin, Isabelle Nelson, et al.. Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy. *Molecular Therapy - Nucleic Acids*, 2018, 10, pp.376 - 386. 10.1016/j.omtn.2017.12.012 . hal-03269960

**HAL Id: hal-03269960**

**<https://hal.sorbonne-universite.fr/hal-03269960>**

Submitted on 24 Jun 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Gene Therapy via *Trans*-Splicing for *LMNA*-Related Congenital Muscular Dystrophy

Feriel Azibani,<sup>1</sup> Astrid Brull,<sup>1</sup> Ludovic Arandel,<sup>1</sup> Maud Beuvin,<sup>1</sup> Isabelle Nelson,<sup>1</sup> Arnaud Jollet,<sup>1</sup> Esma Ziat,<sup>1</sup> Bernard Prudhon,<sup>1</sup> Sofia Benkhelifa-Ziyyat,<sup>1</sup> Marc Bitoun,<sup>1</sup> Stéphanie Lorain,<sup>1</sup> Gisèle Bonne,<sup>1,2</sup> and Anne T. Bertrand<sup>1,2</sup>

<sup>1</sup>Sorbonne Université, INSERM UMRS\_974, Center of Research in Myology, 75013 Paris, France

We assessed the potential of *Lmna*-mRNA repair by spliceosome-mediated RNA *trans*-splicing as a therapeutic approach for *LMNA*-related congenital muscular dystrophy. This gene therapy strategy leads to reduction of mutated transcript expression for the benefit of corresponding wild-type (WT) transcripts. We developed 5'-RNA *pre-trans*-splicing molecules containing the first five exons of *Lmna* and targeting intron 5 of *Lmna* pre-mRNA. Among nine *pre-trans*-splicing molecules, differing in the targeted sequence in intron 5 and tested in C2C12 myoblasts, three induced *trans*-splicing events on endogenous *Lmna* mRNA and confirmed at protein level. Further analyses performed in primary myotubes derived from an *LMNA*-related congenital muscular dystrophy (L-CMD) mouse model led to a partial rescue of the mutant phenotype. Finally, we tested this approach *in vivo* using adeno-associated virus (AAV) delivery in newborn mice and showed that *trans*-splicing events occurred in WT mice 50 days after AAV delivery, although at a low rate. Altogether, while these results provide the first evidence for reprogramming *LMNA* mRNA *in vitro*, strategies to improve the rate of *trans*-splicing events still need to be developed for efficient application of this therapeutic approach *in vivo*.

## INTRODUCTION

A-type lamins (lamin A and C) are intermediate filament proteins expressed in differentiated cells.<sup>1</sup> Together with B-type lamins, they form the nuclear lamina, an organized meshwork found underneath the inner nuclear envelope.<sup>2</sup> They are thought to play a key role in nuclear resistance to mechanical stress, thus maintaining cell integrity. A-type lamins are also present in the nucleoplasm,<sup>3</sup> where they regulate gene expression through interaction with chromatin, nuclear histones, and transcription factors.<sup>4</sup>

Lamins A and C (hereafter referred to as lamin A/C) are produced by alternative splicing of the *LMNA* gene, located on human chromosome 1q21. Since the discovery of the first mutation,<sup>5</sup> 464 mutations have been reported (<http://www.umd.be/LMNA/>). These mutations have been related to more than 10 distinct genetic diseases, commonly named laminopathies.<sup>4,6</sup>

*LMNA*-related congenital muscular dystrophy (L-CMD) has been described as an autosomal dominant muscle disorder related to a dominant *de novo* mutation in *LMNA*, so far the most severe form of striated muscle laminopathies.<sup>7</sup> L-CMD is characterized by an onset before the age of 2 years of major muscle atrophy and weakness mainly affecting axial muscles, leading to complete absence of or limited motor achievements, together with important multiple joint contractures sparing elbows, and severe respiratory insufficiency that requires continuous mechanical ventilation. Identification of cardiac arrhythmias suggested a cardiac involvement in these patients. Our team reported the phenotype of knock-in *Lmna*<sup>ΔK32</sup> mice, reproducing an L-CMD mutation.<sup>8–10</sup> Homozygous *Lmna*<sup>ΔK32</sup> mice rapidly exhibit generalized growth retardation and develop striated muscles and adipose tissue maturation defects, leading to their premature death in their third week of life.<sup>8</sup> Interestingly, while *Lmna* mRNA levels were unaffected in mutant mice, lamin A/C protein level was strongly reduced, representing only 20% of that observed in the wild-type (WT) mice tissues. Moreover, mutant A-type lamins were absent at the nuclear periphery and found exclusively in the nucleoplasm. Both decreased expression and mislocalization of lamin A/C are thought to contribute to the development of the disease.

In the present study, we investigated the potential interest of spliceosome-mediated RNA *trans*-splicing (SMaRT) as a therapeutic strategy for L-CMD. The SMaRT approach targets RNA at the pre-mRNA level and converts the endogenous mutated sequences to WT ones.<sup>11–13</sup> This is achieved by expressing *pre-trans*-spliced molecules (PTMs) containing the WT coding sequence, a strong splicing site and a binding domain to enable the specific binding of the PTMs to the targeted pre-mRNA. This technology has been mainly used to replace 3' exons, but it can also be used to target the replacement of 5' or internal exons. Considering the natural alternative splicing of A-type lamins occurring in a distal exon (exon 10


Received 6 May 2017; accepted 20 December 2017;  
<https://doi.org/10.1016/j.omtn.2017.12.012>.

<sup>2</sup>These authors contributed equally to this work.

**Correspondence:** Anne T. Bertrand, Sorbonne Université, INSERM UMRS\_974, Center of Research in Myology, 47 Boulevard de l'Hôpital, 75013 Paris, France.

**E-mail:** [a.bertrand@institut-myologie.org](mailto:a.bertrand@institut-myologie.org)





**Figure 1. 5' *Trans*-Splicing Strategy for *Lmna* Transcripts**

(A) Schematic illustration of part of the vector encoding for a pre-*trans*-splicing molecule (PTM). The PTM is a transcript comprising the FLAG coding sequence followed by the first five *Lmna* exons (WT *Lmna* ex 1–5), a 5' splice site (5'SS) followed by a downstream intronic splicing enhancer (DISE), and a binding domain (BD) of 150 bp complementary to *Lmna* intron 5. PTM sequences are placed under control of a CMV promoter ( $P_{CMV}$ ). An intronic sequence was added to stabilize the transcript. (B) Schematic representation of *Lmna* pre-mRNA and PTMs. The mouse *Lmna* pre-messenger consists of exons (boxes) and introns (lines). White boxes represent coding sequences, and gray boxes represent non-coding sequence for prelamin A. Intronic size lengths are indicated. The red arrow refers to localization of the  $\Delta K32$  mutation in exon 1. Below, an enlarged view of intron 5 shows the localization of the different designed binding domains. (C) Schematic representation of a *trans*-spliced mRNA molecule and the different primers used to characterize *trans*-spliced/repaired mRNA (F-FLAG and R-*Lmna* exon 7), PTMs (F-FLAG and R-*Lmna* exon 1), and total (endogenous and *trans*-spliced) *Lmna* molecules (F-*Lmna* exon 1 and R-*Lmna* exon 1). Primers used for nested qPCR of *trans*-spliced *Lmna* transcripts are F-FLAG and R-*Lmna* exon 6-1 for the first PCR, followed by F-*Lmna* exon 2 and R-*Lmna* exon 6-2 for the qPCR.

among 12 in total) and the high incidence of *LMNA* mutations in the first exons in L-CMD patients, we took the option of targeting the intron 5 of *Lmna* pre-mRNA by a 5'-*trans*-splicing strategy. We investigate here the feasibility of repairing *LMNA* transcripts by the SMART strategy using AAV delivery both *in vitro* and *in vivo*.

## RESULTS


### PTM Engineering and Selection

Several plasmids encoding PTMs targeting *Lmna* intron 5 were designed (Figure 1A). They all harbor the FLAG-WT *Lmna* exons 1–5 cDNA followed by a canonical 5' splice donor site sequence and a downstream intronic sequence enhancer element to increase the *trans*-splicing efficiency<sup>14,15</sup> and various binding domains (BDs). Nine PTMs were designed, differing in their BDs with respect to the position they target in intron 5 (Figure 1B; Table S1) and called PTM-BD. The expected *trans*-spliced product is composed of exogenous FLAG and exons 1–5 sequences and the endogenous exons 6–12 (Figure 1C). As negative controls that do not bind to intron 5, and thus should not induce 5' *trans*-splicing events, we designed a PTM without BD (called PTM-0) and for each PTM-BD a specific negative control harboring an inverted BD sequence and called PTM-BDinv.

To evaluate the efficacy of *Lmna* *trans*-splicing *in vitro*, we performed transient transfection of the different constructs in C2C12 myoblasts. We did not observe expression of *trans*-spliced lamin A/C by western blotting using either FLAG or lamin A/C antibodies with any of the PTM, probably because of the low *trans*-splicing

efficiency (Figure S1A). Hence, we chose to assess for the expression of *trans*-spliced molecules by PCR using primers that specifically amplify the *trans*-spliced molecules (F-FLAG and R-*Lmna* exon 7; Figure 1C; Table S2). Using such primers, we identified *trans*-spliced molecules when using PTM-BD3, -BD4, and -BD9 (Figure 2A), but not when using other PTM-BDs (data not shown) and negative controls (corresponding PTM-BDinv and PTM-0). We excluded the possibility that the absence of *trans*-splicing events when using PTM-BD1, -BD2, -BD5, -BD6, -BD7, and -BD8 was due to a too low transfection efficiency using primers that recognized PTM and *trans*-spliced mRNA (F-FLAG and R-*Lmna* exon 1). Total *Lmna* mRNA levels were evaluated using primers localized in exon 1 (F-*Lmna* exon 1 and R-*Lmna* exon 1) (Figures 1C and 2A). To fully confirm the identity of amplicons from F-FLAG/R-*Lmna* exon 7 PCR, we cloned and then sequenced the PCR products from C2C12 transfected with PTM-BD3, -BD4, and -BD9. The presence of a FLAG sequence directly followed by *Lmna* exons including a correct exon 5-to-exon 6 junction attested for a *trans*-spliced *Lmna* mRNA (shown for PTM-BD3 in Figure 2B). We then compared the *trans*-splicing rate between PTM-BD3-, -BD4-, and -BD9-transfected C2C12 by nested qPCR. Although the level of *trans*-splicing observed after PTM-BD9 transfection is lower than that obtained after PTM-BD3 or -BD4, it is not statistically significant (Figure 2C).

We investigated whether the *trans*-spliced *Lmna* mRNAs were translated into proteins properly localized at the nuclear envelope by immunofluorescence (nine independent experiments performed).



**Figure 2. Evaluation of PTM's Efficacy in C2C12 Cells**

(A) PCR analysis was performed with primers localized on *Lmna* mRNA (Figure 1C), on RNA extracts from C2C12 myoblasts that were either non-transfected (NT) or transfected for 48 hr with PTM-0, PTM-BD, and PTM-BDinv plasmids. (B) Sequencing of *trans*-spliced *Lmna* amplicons from PTM-BD3-transfected cells after subcloning confirmed *trans*-splicing events with the junction between the exogenous FLAG-*Lmna* exons 1–5 (highlighted in orange and blue) with endogenous *Lmna* exon 6 and the following exons. (C) Bar graph showing the level of lamin A/C mRNA expression by nested qPCR. BD3, transfected with pSMD2-PTM-BD3 (n = 4); BD4, transfected with pSMD2-PTM-BD4 (n = 3); BD9, transfected with pSMD2-PTM-BD9 (n = 5). Differences are not statistically significant. Error bars correspond to SEM. (D) Immunofluorescence analysis of NT or transfected C2C12 with PTM-0, PTM-BD3, PTM-BD3inv. Cells were double-stained with anti-FLAG (green) and anti-Lamin A/C (red) antibodies. Nuclei were stained with DAPI (blue). Arrows show a positive FLAG-tagged nucleus. Scale bar: 10  $\mu$ m.

In order to better understand the successful *trans*-splicing using PTM-BD3, -BD4, and -BD9 compared with the other BDs, we first evaluated the GC content that is known to impact on the level of RNA production.<sup>16</sup> Interestingly, the GC content of the nine PTM-BDs was not significantly different. We then hypothesize that having less secondary structure in the binding domain might well favor recombination with the intronic sequence. We analyzed RNA folding of each PTM-BD (using RNAfold, The ViennaRNA Package) and found less secondary structures such as loops and hairpins for PTM-BD3, -BD4, and -BD9 compared with other PTM-BDs.


Altogether, results obtained on C2C12 cells using 5' *trans*-splicing molecules were very encouraging and we hence decided to test the efficacy of PTM-BD3, -BD4, and -BD9 in myotubes from an L-CMD mouse model.

#### Cellular and Molecular Defects of Homozygous *Lmna* <sup>$\Delta$ K32</sup> Primary Mouse Myoblasts in Culture

We have reported previously that lamin A/C protein levels are highly reduced in homozygous

Using a FLAG antibody, we successfully detected a FLAG signal in 17% of C2C12 myoblasts (mean from three independent experiments with at least 174 cells counted per experiment). This signal was found at the nuclear rim, colocalized with the A-type lamin signal (Figure 2D for PTM-BD3; Figure S1B for PTM-BD4 and -BD9). No signal was detected by immunofluorescence in non-transfected (NT) conditions or after transfection with control PTM-BD3inv or PTM-0.

*Lmna* <sup>$\Delta$ K32</sup> mouse tissues and that the mutant lamin is unable to assemble under the inner nuclear membrane, and hence is only found throughout the nucleoplasm.<sup>8,17</sup> We checked here on cultured primary myoblasts and myotubes isolated from WT and homozygous *Lmna* <sup>$\Delta$ K32</sup> mouse tibialis anterior (TA) muscles. Western blot analysis showed a decrease in lamin A/C protein levels in mutant myoblasts compared with WT cells, while other nuclear envelope proteins such



**Figure 3. Decreased Expression and Abnormal Localization of  $\Delta$ 32-Lamin A/C in Mouse Mutant Muscle Cells**


(A) Representative western blot analysis for mouse primary WT and mutant ( $\Delta$ K32/ $\Delta$ K32) myoblasts (Mb) and myotubes (Mt; 24 hr of differentiation) probed for lamin A/C, lamin B1, and emerlin proteins relative to vinculin. (B and C) Immunofluorescent confocal micrographs of WT and mutant myoblasts (B) and 24-hr differentiated myotubes (C), stained for lamin A/C, emerlin, and lamin B1. Scale bars: 10  $\mu$ m.

as emerlin or lamin B1 levels were unchanged (Figure 3A). Despite a moderate differentiation-dependent increase of lamin A/C expression in WT, the decreased lamin A/C expression level was maintained in mutant myotubes with only 40%–60% residual protein expression. We also investigated the localization of WT and mutant lamin A/C proteins by immunostaining. In proliferating myoblasts,  $\Delta$ K32-lamin A/C was found dispersed throughout the nucleoplasm, whereas WT-lamin A/C was abundantly located at the nuclear envelope and sparsely in the nucleoplasm (Figure 3B). Nuclei of  $\Delta$ K32-myoblasts also showed an elongated shape, as reported previously in human cells and other animal models with mutations in lamin A/C. In addition, if no defect was found for lamin B1 localization, we observed a decreased emerlin staining at the nuclear periphery and an increase in the cytoplasm of mutant compared with WT myoblasts. During myoblast differentiation, mutant myotubes displayed a unique and severely misshapen DNA mass stained with DAPI (data not shown) that could correspond to the aggregation or to the fusion of extremely soft and deformable nuclei. Its nucleoplasm is strongly stained with lamin A/C antibody, while its nuclear envelope only poorly reacts with both emerlin and lamin B1 antibodies that mainly mark perinuclear aggregates (Figure 3C). The defects observed in these cells therefore represent good readouts for *trans*-splicing gene therapy.

#### Increased Proportion of A-Type Lamins at the Nuclear Envelope after *Lmna* mRNA *Trans*-Splicing in Mouse Primary *Lmna* <sup>$\Delta$ K32</sup> Myotubes


To allow gene transfer in mouse primary myotubes, we produced AAV serotypes 2/9. In our hands, transduction of mouse primary myotubes using a control AAV2/9 encoding for GFP resulted in 90% of GFP<sup>+</sup> cells (see Figure S2). In addition to AAV2/9-PTM-BD3, -BD4, and -BD9, we produced control AAVs: one containing the PTM sequence without BD (AAV2/9-PTM-0) and three others with the inverted BD3, BD4, and BD9. Following the transduction of mutant myotubes, we evaluated *trans*-splicing at the mRNA level. All PTM mRNAs (PTM-0, PTM-BD3, and PTM-BD3inv) were expressed in transduced myotubes, as attested by the presence of a PCR product at the expected molecular weight when using F-FLAG and R-*Lmna* exon1 primers (Figure 4A). Using primers specific for *trans*-spliced mRNA, a faint band was observed at the right molecular weight in AAV2/9-PTM-BD3-transduced myotubes corresponding to repaired *Lmna* transcripts, but not in control transduced myotubes (shown for AAV2/9-PTM-BD3 in Figure 4A). Sequencing of the cloned PCR product showed the presence of exogenous FLAG-*Lmna* exons 1–5 and endogenous *Lmna* exon 6 with an exact junction exon 5-exon 6 (Figure 4B).

We further characterized transduced mutant myotubes by immunostaining against FLAG and observed 49% of positive cells (mean of two independent experiments, with at least 191 nuclei counted per experiment) (Figure 4C). Compared with results obtained in C2C12, we found the FLAG staining to be more broadly distributed within the nucleus, although it is enriched at the nuclear envelope in eight independent experiments. These FLAG<sup>+</sup> nuclei also have an increased proportion of lamin A/C at the nuclear envelope



**Figure 4. Detection of Repaired *Lmna* mRNA Induced by 5' *Trans*-Splicing in Mouse Mutant Primary Myotubes**

(A) PCR analysis was performed on RNA extracts of mouse primary mutant myotubes transduced or not (NT) for 7 days with AAV2/9 expressing PTM-0, PTM-BD3, or PTM-BD3inv using primers described in Figure 1C and Table S2. (B) Sequencing of the F-FLAG/R-*Lmna* exon 7 cloned amplicons from AAV2/9-PTM-BD3-transduced cells confirmed *trans*-splicing events with the junction between the exogenous FLAG-*Lmna* exons 1–5 (highlighted in orange and blue) and endogenous *Lmna* exon 6 and the following exons. (C) Immunofluorescence analysis of mutant myotubes that were non-transduced (NT) or transduced with AAV2/9-PTM-0, -PTM-BD3, and -PTM-BD3inv. Cells were double-stained with anti-FLAG (green) and anti-Lamin A/C (red) antibodies. Nuclei were stained with DAPI (blue). Arrows show a FLAG<sup>+</sup> nucleus. Scale bar: 10  $\mu$ m. (D) Scatterplot representing the percentage of laminin A/C staining found at the nuclear periphery in wild-type (WT; n = 19) and non-transduced (NT; n = 40) or PTM-BD3- (n = 40), PTM-BD4- (n = 24), or PTM-BD9 (n = 41)-transduced mutant myotubes. All groups are statistically different from WT ( $p < 0.001$ ), while only PTM-BD3 and PTM-BD4 are statistically different from NT ( $p < 0.01$ ). Error bars correspond to SEM.



**Figure 5. 5' Trans-Splicing of *Lmna* Improves the Nuclear Phenotype of Mutant Myotubes**

(A and B) Immunofluorescence analysis of mutant myotubes that were non-transduced (NT) or transduced with AAV2/9-PTM-0, -PTM-BD3, and -PTM-BD3inv. Cells were differentiated and transduced for 7 days and then stained with lamin A/C (green)/emerin (red) (A) or FLAG (green)/Lamin B1 (red) (B). Nuclei were stained with DAPI (blue). Arrows point to repaired nuclei. Scale bars: 10  $\mu$ m. (C) Representative confocal images of DAPI-stained myotubes that were either non-transduced (NT) or transduced with AAV2/9-PTM-BD3, and scatterplot showing the distribution and the mean size of nuclei long axis (NT:  $n = 107$ ; PTM-BD3:  $n = 137$ ). Error bars correspond to SEM.

compared with non-transduced (NT) or control transduced mutant myotubes (shown for AAV2/9-PTM-BD3 and controls in Figure 4C and for AAV2/9-BD4 and -BD9 in Figure S3A). Measurement of the fluorescence intensity of lamin A/C staining at the nuclear periphery or at the nucleoplasm reveals a significant increase in the proportion of peripheral lamin A/C after PTM-BD3 and PTM-BD4 transduction compared with NT cells ( $p < 0.01$ ), but not after PTM-BD9 transduction (Figure 4D). Interestingly, even if no signal was obtained by western blot using the FLAG antibody, a faint increase in A-type lamin protein level was observed after transduction of mutant myotubes with AAV2/9-PTM-BD3 and -BD4 (Figure S4), indirectly confirming the occurrence of *trans*-splicing.


#### ***Lmna* Trans-Splicing Improves Mutant Myotube Phenotype**

While NT or AAV2/9-PTM-0-transduced mutant myotubes displayed abnormal distribution of emerin and lamin B1 proteins, a great proportion of cells transduced with AAV2/9-PTM-BD3 showed a better staining for emerin (Figure 5A; 17% of FLAG<sup>+</sup> and FLAG<sup>-</sup> nuclei; mean of two independent experiments, with at least 83 cells counted per experiment; see a lower magnification and a zoom-in in Figure S5A) and lamin B1 (Figure 5B; 20% of FLAG<sup>+</sup> and FLAG<sup>-</sup> nuclei; mean of two independent experiments with at least 90 nuclei counted per experiment; see a lower magnification and zoom-in in Figure S5B) at the nuclear rim that increase in intensity (white arrow) and with a disappearance of protein aggregates. Similar results were obtained with AAV2/9-PTM-BD4 and -BD9 (Figure S3B).

We evaluated whether the nuclear elongation was improved after PTM-BD3 transduction by measuring the nuclear long and short axes of all nuclei (FLAG<sup>+</sup> and FLAG<sup>-</sup>). Although the short axis did not vary between the transduced and non-transduced cells, a significant decrease of 55% of the length of the long axis was observed after PTM-BD3 transduction (Figure 5C; mean of two independent experiments, with at least 44 nuclei counted per condition and per experiment). This result showed that abnormally shaped nuclei can regain better shape by a partial lamin A/C rescue following *trans*-splicing.

#### ***In Vivo* Evaluation of Trans-Splicing of *Lmna* mRNA**

We then performed systemic injections of AAV2/9-empty, AAV2/9-PTM-BD3, -BD4, and -BD9 in newborn WT mice ( $n = 4$  per construct;  $10^{11}$  virus genomes [vg]/mouse) and sacrificed the mice 50 days post-injection. Despite a good transduction efficiency attested by a strong band after PCR specific for the PTM, we detected an extremely faint



**Figure 6. Evidence for Reprogramming *Lmna* mRNA and Protein by 5' Trans-Splicing *In Vivo***

(A) PCR analysis was performed on RNA extracts of heart tissue from WT mice 50 days after systemic injection of AAV2/9-empty or expressing PTM-0, PTM-BD4, or PTM-BD4inv using primers described in Figure 1C and Table S2. (B) Sequencing of F-FLAG/R-*Lmna* exon 7 cloned amplicons from heart from mice 50 days after systemic injection with AAV2/9-PTM-BD4 confirmed *trans*-splicing events with the junction between the exogenous FLAG-*Lmna* exons 1–5 (highlighted in orange and blue) and endogenous *Lmna* exon 6. (C) Bar graph showing the level of lamin A/C mRNA expression by nested qPCR in hearts of WT mice 50 days after systemic injection of AAV2/9-PTM-BD3, -BD4, or -BD9.  $n = 4$  per group, and differences are not statistically significant. Error bars correspond to SEM. (D) H&E staining of striated muscle sections from WT mice 50 days after systemic injection with AAV2/9-empty or expressing PTM-0, PTM-BD4 or PTM-BD4inv. Scale bar: 50  $\mu\text{m}$ . (E) Immunofluorescence analysis of heart sections from WT mice 50 days after systemic injection of AAV2/9-PTM-0, -PTM-BD4, and -PTM-BD4inv. Cells were double-stained with anti-FLAG (green) and anti-Lamin A/C (red) antibodies. Nuclei were stained with DAPI (blue). Scale bar: 10  $\mu\text{m}$ . (F) Immunofluorescence analysis of heart sections from WT mouse 50 days after systemic injection of AAV2/9-PTM-BD4. Cells were double-stained with anti-FLAG (green) and anti-desmin (red) antibodies. Nuclei were stained with DAPI (blue). Arrows point to a positive FLAG-tagged nucleus. Scale bar: 10  $\mu\text{m}$ . (G) Bar graph showing the level of lamin A/C mRNA expression by nested qPCR in hearts of mice 15 ( $n = 3$ ) or 50 days ( $n = 4$ ) after systemic injection of AAV2/9-PTM-BD4. Differences are not statistically significant. Error bars correspond to SEM. Gast, gastrocnemius; TA, tibialis anterior.

band for *trans*-spliced molecules whatever the virus construct (Figure 6A). As performed previously, to clearly prove the presence of *trans*-splicing *in vivo*, we cloned the bands and subsequently sequenced the clones (Figure 6B). Finally, we compared the level of *trans*-splicing by nested qPCR on heart tissues after AAV2/9-PTM-BD3, -BD4, or -BD9 delivery. Although the level of *trans*-splicing seems higher after AAV2/9-PTM-BD4 delivery, the differences between the three groups are not statistically significant (Figure 6C).

Observation of transversal sections of different skeletal muscles and heart stained with H&E demonstrated that there was no toxicity consecutive to AAV injections and/or PTM expression (shown for AAV2/9-PTM-BD4 in Figure 6D and for AAV2/9-PTM-BD3 in Figure S6A). Evaluation of *trans*-splicing at the protein level by immunofluorescence successfully detected positive events in the heart after AAV2/9-PTM-BD4 delivery, but not after transduction with control vectors (Figure 6E). Indeed, a FLAG staining colocalizing with the



endogenous lamin A/C was observed at the nuclear envelope in 6% of transduced cells in cardiac sections (mean of two independent experiments with at least 292 nuclei counted per experiment). Unfortunately, a double immunostaining for FLAG and desmin showed that among these FLAG<sup>+</sup> nuclei, only a few corresponded to cardiomyocytes (Figure 6F). A low number of positive nuclei was also observed in other tissues, including TA (Figure S6B) or gastrocnemius muscles and liver (data not shown).

Although the *trans*-splicing efficiency appears to be extremely low *in vivo*, we decided to test whether our best PTM virus (based on our *in vitro* and *in vivo* analyses) was able to alleviate the severe phenotype observed in homozygous *Lmna*<sup>ΔK32</sup> mice.<sup>8</sup> We hence performed systemic injection of AAV2/9-PTM-BD4 in newborn mice obtained from *Lmna*<sup>ΔK32</sup> heterozygous breeders before their genotyping (n = 10; 10<sup>11</sup> vg/mouse). Homozygous mice (n = 2) were carefully followed until their natural death. They respectively died at days 14 and 15, hence showing no benefits in terms of survival after AAV2/9-PTM-BD4 injection.<sup>8</sup> WT and heterozygous mouse littermates were sacrificed 15 days post-injection, and WT, heterozygous, and homozygous mouse tissues were processed for analysis. PCR on heart, quadriceps, and gastrocnemius muscles using primers specific for PTM mRNA (F-FLAG and R-*Lmna* exon 1) were all positive, attesting that the different tissues were properly transduced and the virus expressed. PCRs for *trans*-spliced *Lmna* mRNA (F-FLAG and R-*Lmna* exon 7) were all negative (Figure S6C); however, increasing the PCR sensitivity using nested qPCR, we were able to observe *trans*-splicing events in all 15-day-old transduced animals to a level that is similar to that observed 50 days post-transduction (Figure 6G).

## DISCUSSION

Since the time when RNA *trans*-splicing was discovered,<sup>18,19</sup> this technique has been highlighted in different *in vitro* and *in vivo* studies for its safety and specificity to repair genetic defects associated with human diseases.<sup>20–28</sup> In this study, we demonstrate the challenges of RNA repair of *Lmna* messengers in a context of a particularly severe autosomal dominant genetic disease, as L-CMD. To date, no curative treatment exists for L-CMD, and management of patients is largely supportive. The conversion of the mutant transcript into a normal transcript has many advantages, including a good alternative to classical gene replacement strategies that may lead to toxic effect because of lamin A/C overexpression.<sup>29,30</sup> It also corrects the dominant-negative aspect of the pathology that has been largely described in the past by reducing the expression of the mutant proteins.<sup>31</sup> Moreover, expression of *trans*-spliced molecules is maintained under the endogenous regulation of the targeted mRNA, which avoids undesirable ectopic expression.

The vast majority of L-CMD cases harbor mutations in exons 1 (36.5%) and 4 (32.5%) (G. Bonne, personal communication) (<http://www.umd.be/LMNA/>). While the majority of published reports has been concentrated on the use of 3' *trans*-splicing approach,<sup>20,22,28,32</sup> we took the option of the 5' *trans*-splicing. This strategy has the advantage to leave the natural alternative splicing

of the *Lmna* mRNA (taking place in exon 10) unaffected. Moreover, the *Lmna* gene has several introns that are too small to be targeted for *trans*-splicing (Figure 1A). For this proof of principle, we chose to target the *Lmna* intron 5, which is more than 1,000 base length and allows to target 51% of the described LMNA mutations (G. Bonne, personal communication) (<http://www.umd.be/LMNA/>).

In this study, PTM-BD screening in mouse myoblasts evaluated at the mRNA and protein levels has displayed positive *trans*-splicing events for three out of the nine designed PTM-BDs. There are no rules to design BD sequences.<sup>12,33</sup> All designed BDs in our study specifically target intron 5 of *Lmna* pre-mRNA and are 150-bp-long sequences, which have been shown to limit off-targets.<sup>34</sup> The toxicity of the peptides translated from PTM, described in 3' *trans*-splicing strategies,<sup>25,35</sup> was avoided in our 5' strategy by the deletion of the poly-adenylation sequence. Moreover, we have shown that having binding domains less prone to form secondary structures might increase the rate of *trans*-splicing events. Finally, different studies have suggested that binding domains targeting 5' regions of introns are more efficient than the ones targeting 3' regions.<sup>26,35</sup> Interestingly, two of our three PTM-BDs giving positive results are indeed targeting the 5' region of *Lmna* intron 5.

In a pathological context, PTM-BD3 and -BD4 are able to rescue part of the nuclear phenotypes of homozygous *Lmna*<sup>ΔK32</sup> myotubes. Indeed, the localization of lamin A/C was increased at the nuclear periphery in FLAG<sup>+</sup> cells. We suppose that the FLAG signal is less well localized to the nuclear envelope of mutant myotubes compared with experiments performed in C2C12 myoblasts, because corrected/*trans*-spliced lamin A/C proteins are interacting and polymerizing with mutant lamin A/C. Furthermore, both emerin and lamin B1 mislocalization and nuclear deformation were partially restored in those FLAG<sup>+</sup> cells. However, the absence of detection of *trans*-spliced lamin A/C proteins by western blot, as well as the faint FLAG staining on immunofluorescence, underlines the low *trans*-splicing rate already described by others.<sup>15,28</sup> Using primary mouse myoblasts that restrict the transduction time to only few days may also explain this latter point. Interestingly, PTM-BD9 that is not able to increase significantly the proportion of lamin A/C found at the nuclear periphery is also the PTM that leads to the lower level of lamin A/C mRNA expression after nested qPCR.

Considering the ubiquitous expression of lamin A/C and the potential interest of modulating the ratio of mutant versus WT proteins in striated muscles of L-CMD patients, we chose to use AAV2/9 vectors that show a good tropism for heart and skeletal muscles.<sup>36</sup> Evaluation of *trans*-splicing events in tissues from systemic injected pups showed an extremely modest increase in lamin A/C mRNA expression, observed only after a nested PCR, as well as the presence of a few FLAG<sup>+</sup> cells dispersed throughout the various analyzed tissues (i.e., heart, skeletal muscles, liver). This level is way too low to lead to any obvious benefits for the homozygous *Lmna*<sup>ΔK32</sup> mice like an increase in the survival. Increasing the time between AAV delivery and analysis does not result in the accumulation of *trans*-spliced

protein, probably because of the fast turnover of lamin A/C. In addition, if systemic administration of AAV2/9 particles is known to efficiently transduce the heart,<sup>37</sup> we found the FLAG staining to be more in the nuclei of vessel cells than cardiomyocytes. The mechanism underlying the impaired *trans*-splicing in cardiomyocytes has yet to be elucidated; a possibility exists that changing the promoter from CMV to a cell-specific promoter might solve this issue. Several other options may be tested to increase *Lmna* *trans*-splicing efficiency: (1) the use of self-complementary AAV, which is already double stranded and hence needs less time to be expressed and may also lead to higher expression in tissues;<sup>38</sup> (2) a combo treatment of PTMs with antisense oligonucleotides to reduce *cis*-splicing and hence favor the *trans*-splicing of *Lmna* gene;<sup>39</sup> and (3) the use of codon-optimized PTMs to increase translation of the *trans*-spliced mRNA.<sup>28</sup>

Overall, this proof of principle pinpoints onto the crucial importance of reducing the expression of the highly toxic mutated lamin A/C and increasing the expression of WT lamin A/C in an extremely short time. In addition, the safety and the advantages of using PTM-BD molecules that may target more than 70% of L-CMD patients have to be taken in account. Despite the low efficiency of repaired mutated lamin A/C by *trans*-splicing that we and other teams have observed, this technique remains a promising and hopeful RNA therapy for dominant genetic diseases.

## MATERIALS AND METHODS

### Plasmid Construction and Adeno-Associated Virus Production

The coding sequence of the PTM was generated by PCR of mouse WT cDNA with a forward primer containing a SacII restriction site, the Kozak sequence, followed by the FLAG sequence and the first 19 nucleotides of *Lmna* exon 1. The reverse primer contained a SacII restriction site, as well as: (1) downstream intronic splicing enhancer element (DISE) from the rat fibroblast growth factor receptor 2 (*Fgfr2*) gene, followed by (2) the 5' canonical splice donor site sequence and (3) the last 26 nucleotides of *Lmna* exon 5. The different binding domains were obtained by PCR of WT mouse genomic DNA using a forward primer containing an EcoRI restriction site and 21 nucleotides of *Lmna* intron 5 (Table S1). The reverse primer contained an EcoRI restriction site and 21 nucleotides complementary to *Lmna* intron 5. PCR products were sequentially cloned into pSMD2<sup>40</sup> under a CMV promoter and deleted of its SV40 polyA signal. Control plasmid for evaluation of primary myotube transduction efficiency was performed using the same vector backbone with GFP as a coding sequence and its SV40 polyA signal. All constructs were sequenced and quantified using a spectrophotometer. Adeno-associated virus (AAV2/9) vectors were generated using a three-plasmid transfection protocol as described previously.<sup>15,41</sup> Virus titers measured by qPCR ranged from  $7.1 \times 10^{12}$  to  $3.1 \times 10^{13}$  vg/mL.

### Cell Culture, Plasmid Transfection, and AAV Transduction

The mouse C2C12 myoblast and NIH 3T3 fibroblast cell lines were cultured in DMEM (Thermo Fisher Scientific, Courtaboeuf, France) supplemented with 1% penicillin/streptomycin (Thermo Fisher Scientific, Courtaboeuf, France) and 10% fetal bovine serum (Thermo

Fisher Scientific, Courtaboeuf, France). Cells were grown to 70% of confluence in four-well plates, and 1–3  $\mu$ g of DNA was transfected using Lipofectamine 2000 (Thermo Fisher Scientific, Courtaboeuf, France) according to manufacturer's instructions for 48 hr. A pSMD2-CMV plasmid encoding FLAG-human Prelamin A sequence was used as a transfection control. Primary mouse myoblasts from WT and *Lmna* <sup>$\Delta$ K32/ $\Delta$ K32</sup> mutant mice were cultured in DMEM supplemented with 20% fetal bovine serum, 10% donor horse serum (VWR International, Fontenay sous Bois, France), and 1% Chicken Embryo Extract (Sera Laboratories International, West Sussex, UK), as described previously.<sup>42</sup> Differentiation medium consisted of DMEM supplemented with 2% donor horse serum and 0.5% Chicken Embryo Extract. All media contained 1% penicillin/streptomycin. Tissue culture plastic dishes were coated with 10% Matrigel (Corning, Avon, France). Twenty-four hours after plating, cells were transduced with AAV2/9 vectors at  $2.6 \times 10^5$  to  $6.0 \times 10^5$  MOI for 7 days in differentiation medium. All cells were grown in a humidified incubator at 37°C in 5% CO<sub>2</sub>.

### Mouse Lines

*Lmna* <sup>$\Delta$ K32</sup> (corresponding to *Lmna*tm2.1Gbon according to MGI nomenclature) mice were described previously.<sup>8–10</sup> All mouse procedures were done according to protocols conformed to the French laws, and regulations concerning the use of animals for research were approved by an external ethical committee (approval no. 00972.03 and 00971.02; delivered by the French Ministry of Higher Education and Scientific Research).

Systemic injections of the different AAV2/9 ( $10^{11}$  vg/mouse) were performed into the temporal vein of 2-day-old mice. WT pups were sacrificed 15 or 50 days post-injection. Tissue sampling and processing were done post-mortem.

### Quantification of *Trans*-Splicing Rate at RNA Level

Total RNA was isolated using the RNeasy fibrous tissue Mini Kit (QIAGEN, Courtaboeuf, France) according to manufacturer's instructions and reverse transcribed using Superscript III kit (Thermo Fisher Scientific, Courtaboeuf, France) with 1–2  $\mu$ g of total RNA. Endpoint PCR amplification was performed using PCR Super Mix (Thermo Fisher Scientific, Courtaboeuf, France) with different primer pairs (Table S2). PCR products were visualized on 1% or 2% agarose gels. The band corresponding to the *trans*-spliced molecule (F-FLAG/R-*Lmna* exon 7; 1,398 bp) was purified using Nucleospin Gel and PCR clean-up columns (Machery Nagel, Hoerdt, France), cloned in pGEM-T easy vector (Promega, Charbonnières, France), and sequenced.

Nested qPCR was performed as follows: 10 PCR cycles using 2 $\times$  PCR Reddy Mix (Thermo Fisher Scientific, Courtaboeuf, France) and primers specific for *trans*-spliced molecules (F-FLAG and R-*Lmna* exon 6-1; see Table S2). Samples of the first PCR were cleaned using PCR clean-up columns (Machery-Nagel, Hoerdt, France) to remove the first primer set. Two microliters of a 1/20 dilution was used to perform a qPCR using F-*Lmna* exon 2 and R-*Lmna* exon 6-2 primers

with SYBR Green I Master Mix on a Roche LightCycler 480 II (both from Roche, Meylan, France).

### Western Blot

Cell pellets were homogenized in protein extraction buffer (50 mM Tris-HCl [pH 7.5]; 2% SDS; 250 mM sucrose; 75 mM urea; 1 mM dithiothreitol) containing protease/phosphatase inhibitors [25 µg/mL aprotinin, 10 µg/mL leupeptin; 1 mM 4-(2-aminoethyl) benzene sulfonyl fluoride hydrochloride, and 2 mM Na<sub>3</sub>VO<sub>4</sub>]. Protein extracts were quantified with Pierce BCA Protein Assay Kit (Pierce Biotechnology, USA), separated on a SDS-PAGE, and transferred onto nitrocellulose membrane. After blocking, nitrocellulose blots were incubated with primary antibodies directed against lamin A/C (H-110, sc-20681 or E-1, sc-376248; Santa Cruz Biotechnology, Santa Cruz, CA, USA), lamin B1 (C-20, sc-6216 [Santa Cruz Biotechnology, Santa Cruz, CA, USA] and ab16048 [Abcam, Cambridge, UK]), vinculin (V9131; Sigma-Aldrich, Saint Quentin Fallavier, France), and emerin (NCL-clone 4G5; Novocastra, Newcastle, UK) and then with secondary anti-rabbit, anti-goat, or anti-mouse antibodies coupled to horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA, USA). Immunoblots were visualized by Immobilon Western Chemiluminescent HRP Substrate (Millipore, Molsheim, France) on a G Box system using GeneSnap software (Ozyme, Saint Quentin, France).

### Histology and Immunofluorescent Analysis

Seven-micrometer sections were made using a cryostat Leica CM3050S. Frozen sections were stained with H&E staining using standard method and visualized under light microscopy.

For immunostaining, cells and tissue sections were fixed for 10 min in 4% paraformaldehyde, permeabilized in 0.5% Triton X-100 in PBS for 5 min, and then blocked for 1 hr in 10% BSA IgG-free. To avoid unspecific staining, we then incubated the sections with Fab fragment solution (0.2 mg/mL in PBS) for 1 hr at room temperature. Primary antibodies against lamin A/C (N-18, sc-6215 or E-1, sc-376248) and lamin B1 (C-20, sc-6216) were purchased from Santa Cruz Biotechnology, anti-FLAG (F1804) from Sigma-Aldrich (Saint Quentin Fallavier, France), and anti-emerin (NCL-clone 4G5) from Novocastra (Newcastle, UK), while anti-desmin (Ab15200) was purchased from Abcam (Cambridge, UK) and anti-GFP (A10262) from Invitrogen (Life Technologies, Saint-Aubin, France). Secondary antibodies against mouse, rabbit, or donkey were coupled with Alexa Fluor 488 or Alexa Fluor 568 (Life Technologies, Saint-Aubin, France). Preparations were mounted with Vectashield mounting medium containing DAPI (Vector Labs, Burlingame, CA, USA), and confocal images were collected using upright confocal laser-scanning microscope (FV-1000 or FV-1200; Olympus) equipped with a UPlanS-Apo 60×/1.35 NA oil immersion objective lens.

Fluorescence intensity of lamin A/C staining at the nuclear periphery versus the nucleoplasm was evaluated by measuring the corrected total fluorescence intensity (CTCF) of total lamin A/C and the CTCF of nucleoplasmic lamin A/C using ImageJ software. CTCF is calculated using the following formula: Integrated density – (area

of selected cell × mean fluorescence of background readings). Nuclear dimensions were measured from fluorescence profiles using ImageJ software. Two perpendicular line segments were drawn manually on a nuclear cross section with the longest diameter representing the major axis of the nucleus.

### Statistics

Double-blind experiments and result analyses were performed during this study. Measurement of the percentage of peripheral lamin A/C and nuclear dimensions are expressed as means ± SEM. An unpaired two-tailed t test was performed for the nuclear dimension and a one-way ANOVA followed by Tukey's multiple comparison test using GraphPad Prism software. Equal variances were controlled using Bartlett's test.  $p < 0.05$  was considered as statistically significant.

### SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and two tables and can be found with this article online at <https://doi.org/10.1016/j.omtn.2017.12.012>.

### AUTHOR CONTRIBUTIONS

Conceptualization: M. Bitoun, G.B., and A.T.B.; Methodology: F.A., M. Bitoun, S.L., G.B., and A.T.B.; Investigation: F.A., L.A., A.B., M. Beuvin, I.N., A.J., E.Z., B.P., M. Bitoun, and A.T.B.; AAV Production: S.B.-Z.; Writing – Original Draft: F.A.; Writing – Review & Editing: F.A., A.B., I.N., M. Bitoun, S.L., G.B., and A.T.B.; Visualization: F.A., A.B., and A.T.B.; Supervision: G.B. and A.T.B.; Project Administration: G.B. and A.T.B.; Funding Acquisition: G.B. and A.T.B.

### CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

### ACKNOWLEDGMENTS

We are grateful to the Penn Vector Core, Gene Therapy Program, University of Pennsylvania, Philadelphia, for providing the pAAV-9 plasmid (p5E18-VD29) and the vectorology platform of the Centre of Research in Myology-UMRS974 (Paris, France) for AAV production, the Pitié-Salpêtrière Imaging Platform (PICPS) for confocal imaging acquisition facilities, the Animal facility of Pitié-Salpêtrière campus (Centre d'Expérimentation Fonctionnelle, Sorbonne Université-Médecine), and to Joelle Marie for her helpful advice and comments. We would like to thank Delphine Trochet for fruitful discussions and comments. This work was supported by INSERM, the Association Institut de Myologie (AIM), Sorbonne Université-Médecine, the Centre National de la Recherche Scientifique (CNRS), CURE-CMD Foundation, and the Andrés Marcio Foundation.

### REFERENCES

1. Broers, J.L., Ramaekers, F.C., Bonne, G., Yaou, R.B., and Hutchison, C.J. (2006). Nuclear lamins: laminopathies and their role in premature ageing. *Physiol. Rev.* 86, 967–1008.
2. Aebi, U., Cohn, J., Buhle, L., and Gerace, L. (1986). The nuclear lamina is a meshwork of intermediate-type filaments. *Nature* 323, 560–564.



3. Hozák, P., Sasseville, A.M., Raymond, Y., and Cook, P.R. (1995). Lamin proteins form an internal nucleoskeleton as well as a peripheral lamina in human cells. *J. Cell Sci.* *108*, 635–644.
4. Gruenbaum, Y., and Foisner, R. (2015). Lamins: nuclear intermediate filament proteins with fundamental functions in nuclear mechanics and genome regulation. *Annu. Rev. Biochem.* *84*, 131–164.
5. Bonne, G., Di Barletta, M.R., Varnous, S., Bécane, H.M., Hammouda, E.H., Merlini, L., Muntoni, F., Greenberg, C.R., Gary, F., Urtizberea, J.A., et al. (1999). Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. *Nat. Genet.* *21*, 285–288.
6. Bertrand, A.T., Chikhaoui, K., Yaou, R.B., and Bonne, G. (2011). Clinical and genetic heterogeneity in laminopathies. *Biochem. Soc. Trans.* *39*, 1687–1692.
7. Quijano-Roy, S., Mbieleu, B., Bönnemann, C.G., Jeannet, P.Y., Colomer, J., Clarke, N.F., Cuisset, J.M., Roper, H., De Meirleir, L., D'Amico, A., et al. (2008). De novo LMNA mutations cause a new form of congenital muscular dystrophy. *Ann. Neurol.* *64*, 177–186.
8. Bertrand, A.T., Renou, L., Papadopoulos, A., Beuvin, M., Lacène, E., Massart, C., Ottolenghi, C., Decostre, V., Maron, S., Schlossarek, S., et al. (2012). DelK32-lamin A/C has abnormal location and induces incomplete tissue maturation and severe metabolic defects leading to premature death. *Hum. Mol. Genet.* *21*, 1037–1048.
9. Cattin, M.E., Bertrand, A.T., Schlossarek, S., Le Bihan, M.C., Skov Jensen, S., Neuber, C., Crocini, C., Maron, S., Lainé, J., Mougnot, N., et al. (2013). Heterozygous LmndelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity. *Hum. Mol. Genet.* *22*, 3152–3164.
10. Cattin, M.E., Ferry, A., Vignaud, A., Mougnot, N., Jacquet, A., Wahbi, K., Bertrand, A.T., and Bonne, G. (2016). Mutation in lamin A/C sensitizes the myocardium to exercise-induced mechanical stress but has no effect on skeletal muscles in mouse. *Neuromuscul. Disord.* *26*, 490–499.
11. Mitchell, L.G., and McGarrity, G.J. (2005). Gene therapy progress and prospects: reprogramming gene expression by trans-splicing. *Gene Ther.* *12*, 1477–1485.
12. Wally, V., Murauer, E.M., and Bauer, J.W. (2012). Spliceosome-mediated trans-splicing: the therapeutic cut and paste. *J. Invest. Dermatol.* *132*, 1959–1966.
13. Wood, M., Yin, H., and McClorey, G. (2007). Modulating the expression of disease genes with RNA-based therapy. *PLoS Genet.* *3*, e109.
14. Lorain, S., Peccate, C., Le Hir, M., and Garcia, L. (2010). Exon exchange approach to repair Duchenne dystrophin transcripts. *PLoS ONE* *5*, e10894.
15. Mearini, G., Stimpel, D., Krämer, E., Geertz, B., Braren, I., Gedick-Hornung, C., Précigout, G., Müller, O.J., Katus, H.A., Eschenhagen, T., et al. (2013). Repair of Mybp3 mRNA by 5'-trans-splicing in a mouse model of hypertrophic cardiomyopathy. *Mol. Ther. Nucleic Acids* *2*, e102.
16. Kudla, G., Lipinski, L., Caffin, F., Helwak, A., and Zyllicz, M. (2006). High guanine and cytosine content increases mRNA levels in mammalian cells. *PLoS Biol.* *4*, e180.
17. Pilat, U., Dechat, T., Bertrand, A.T., Woisetschläger, N., Gotic, I., Spilka, R., Biadasiewicz, K., Bonne, G., and Foisner, R. (2013). The muscle dystrophy-causing  $\Delta$ K32 lamin A/C mutant does not impair the functions of the nucleoplasmic lamin-A/C-LAP2 $\alpha$  complex in mice. *J. Cell Sci.* *126*, 1753–1762.
18. Solnick, D. (1985). Alternative splicing caused by RNA secondary structure. *Cell* *43*, 667–676.
19. Konarska, M.M., Padgett, R.A., and Sharp, P.A. (1985). Trans splicing of mRNA precursors in vitro. *Cell* *42*, 165–171.
20. Chao, H., Mansfield, S.G., Bartel, R.C., Hiriyanna, S., Mitchell, L.G., Garcia-Blanco, M.A., and Walsh, C.E. (2003). Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. *Nat. Med.* *9*, 1015–1019.
21. Tahara, M., Pergolizzi, R.G., Kobayashi, H., Krause, A., Luettich, K., Lesser, M.L., and Crystal, R.G. (2004). Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. *Nat. Med.* *10*, 835–841.
22. Wally, V., Klausegger, A., Koller, U., Lochmüller, H., Krause, S., Wiche, G., Mitchell, L.G., Hintner, H., and Bauer, J.W. (2008). 5' Trans-splicing repair of the PLEC1 gene. *J. Invest. Dermatol.* *128*, 568–574.
23. Mansfield, S.G., Kole, J., Puttaraju, M., Yang, C.C., Garcia-Blanco, M.A., Cohn, J.A., and Mitchell, L.G. (2000). Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. *Gene Ther.* *7*, 1885–1895.
24. Puttaraju, M., Jamison, S.F., Mansfield, S.G., Garcia-Blanco, M.A., and Mitchell, L.G. (1999). Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. *Nat. Biotechnol.* *17*, 246–252.
25. Puttaraju, M., DiPasquale, J., Baker, C.C., Mitchell, L.G., and Garcia-Blanco, M.A. (2001). Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing. *Mol. Ther.* *4*, 105–114.
26. Berger, A., Lorain, S., Joséphine, C., Desrosiers, M., Peccate, C., Voit, T., Garcia, L., Sahel, J.A., and Bemelmans, A.P. (2015). Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa. *Mol. Ther.* *23*, 918–930.
27. He, X., Liu, F., Yan, J., Zhang, Y., Yan, J., Shang, H., Dou, Q., Zhao, Q., and Song, Y. (2015). Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo. *Sci. Rep.* *5*, 8705.
28. Lorain, S., Peccate, C., Le Hir, M., Griffith, G., Philippi, S., Précigout, G., Mamchaoui, K., Jollet, A., Voit, T., and Garcia, L. (2013). Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches. *Nucleic Acids Res.* *41*, 8391–8402.
29. Bechert, K., Lagos-Quintana, M., Harborth, J., Weber, K., and Osborn, M. (2003). Effects of expressing lamin A mutant protein causing Emery-Dreifuss muscular dystrophy and familial partial lipodystrophy in HeLa cells. *Exp. Cell Res.* *286*, 75–86.
30. Favreau, C., Dubosclard, E., Ostlund, C., Vigouroux, C., Capeau, J., Wehnert, M., Higuier, D., Worman, H.J., Courvalin, J.C., and Buendia, B. (2003). Expression of lamin A mutated in the carboxyl-terminal tail generates an aberrant nuclear phenotype similar to that observed in cells from patients with Dunnigan-type partial lipodystrophy and Emery-Dreifuss muscular dystrophy. *Exp. Cell Res.* *282*, 14–23.
31. Azibani, F., Muchir, A., Vignier, N., Bonne, G., and Bertrand, A.T. (2014). Striated muscle laminopathies. *Semin. Cell Dev. Biol.* *29*, 107–115.
32. Coady, T.H., and Lorson, C.L. (2010). Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. *J. Neurosci.* *30*, 126–130.
33. Koller, U., Hainzl, S., Kocher, T., Hüttner, C., Klausegger, A., Gruber, C., Mayr, E., Wally, V., Bauer, J.W., and Murauer, E.M. (2015). Trans-splicing improvement by the combined application of antisense strategies. *Int. J. Mol. Sci.* *16*, 1179–1191.
34. Berger, A., Maire, S., Gaillard, M.C., Sahel, J.A., Hantraye, P., and Bemelmans, A.P. (2016). mRNA trans-splicing in gene therapy for genetic diseases. *Wiley Interdiscip. Rev. RNA* *7*, 487–498.
35. Monjaret, F., Bourg, N., Suel, L., Roudaut, C., Le Roy, F., Richard, I., and Charton, K. (2014). Cis-splicing and translation of the pre-trans-splicing molecule combine with efficiency in spliceosome-mediated RNA trans-splicing. *Mol. Ther.* *22*, 1176–1187.
36. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J.E. (2008). Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. *Mol. Ther.* *16*, 1073–1080.
37. Inagaki, K., Fuess, S., Storm, T.A., Gibson, G.A., Mctiernan, C.F., Kay, M.A., and Nakai, H. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. *Mol. Ther.* *14*, 45–53.
38. McCarty, D.M. (2008). Self-complementary AAV vectors; advances and applications. *Mol. Ther.* *16*, 1648–1656.
39. Coady, T.H., Baughan, T.D., Shababi, M., Passini, M.A., and Lorson, C.L. (2008). Development of a single vector system that enhances trans-splicing of SMN2 transcripts. *PLoS ONE* *3*, e3468.
40. Snyder, R.O., Spratt, S.K., Lagarde, C., Bohl, D., Kaspar, B., Sloan, B., Cohen, L.K., and Danos, O. (1997). Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. *Hum. Gene Ther.* *8*, 1891–1900.
41. Lorain, S., Gross, D.A., Goyenvall, A., Danos, O., Davoust, J., and Garcia, L. (2008). Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles. *Mol. Ther.* *16*, 541–547.
42. Boudreau, É., Labib, S., Bertrand, A.T., Decostre, V., Bolongo, P.M., Sylvius, N., Bonne, G., and Tesson, F. (2012). Lamin A/C mutants disturb sumo1 localization and sumoylation in vitro and in vivo. *PLoS ONE* *7*, e45918.

OMTN, Volume 10

## Supplemental Information

### Gene Therapy via *Trans*-Splicing for *LMNA*-Related Congenital Muscular Dystrophy

Feriel Azibani, Astrid Brull, Ludovic Arandel, Maud Beuvin, Isabelle Nelson, Arnaud Jollet, Esma Ziat, Bernard Prudhon, Sofia Benkhelifa-Ziyyat, Marc Bitoun, Stéphanie Lorain, Gisèle Bonne, and Anne T. Bertrand






DAPI

GFP


Desmin



Merge
















## Supplemental information

### **Figure S1: Protein evaluation of *trans*-splicing *in vitro*.**

(A) Representative western blot analysis for FLAG and lamin A/C expression relative to Ponceau red from C2C12 cells transfected or not (NT) with FLAG-prelaminA, various PTM-BD and PTM-BDinv. No trans-splicing event is detected by western blot. (B) Immunofluorescence analysis of C2C12 transfected with PTM-BD4 and PTM-BD9. Cells were double-stained with anti-FLAG (green) and anti-Lamin A/C (red) antibodies. Nuclei were stained with DAPI (blue). Arrows point on FLAG+ nuclei. (Scale bar: 10  $\mu$ m).

### **Figure S2: Evaluation of the transduction rate in mouse primary myotubes.**

Immunofluorescent confocal micrographs of WT mouse primary myotubes transduced with AAV2/9-CMV-GFP and stained for GFP (green) and Desmin (red). Nuclei were stained with DAPI (blue). (Scale bar: 100  $\mu$ m).

### **Figure S3: Detection of repaired *Lmna* mRNA induced by 5' *trans*-splicing in mouse**

***Lmna* <sup>$\Delta$ K32/ $\Delta$ K32</sup> primary myotubes.**

Immunofluorescence analysis of *Lmna* <sup>$\Delta$ K32/ $\Delta$ K32</sup> myotubes transduced with AAV2/9-PTM-BD4 and PTM-BD9. Cells were double-stained with anti-FLAG (green) and anti-lamin A/C (red) antibodies (A) or with anti-lamin A/C (green) and anti-emerin (red) antibodies (B). Nuclei were stained with DAPI (blue). Arrows show relocalization of lamin A/C to nuclear envelope. (Scale bar: 10  $\mu$ m).

**Figure S4: *In vitro* validation of *Lmna* 5' *trans*-splicing in primary mouse mutant myotubes.**

Western blot analysis for lamin A/C expression relative to Ponceau red from primary mouse WT myotubes and mutant ( $\Delta$ K32) myotubes transduced either with AAV2/9-PTM-0, -BD3 or -BD4. Transduction with AAV2/9-PTM-BD3 and -BD4 induces a small increase in lamin A/C protein level.

**Figure S5: Improve in emerin and lamin B1 localization after *Lmna* 5' *trans*-splicing *in vitro*.**

Immunofluorescence against emerin (**A**) or lamin B1 (**B**) in non-transduced (NT) or PTM-BD3-transduced primary mutant ( $\Delta$ K32) myotubes. Nuclei are counterstained with DAPI. Stars highlighted nuclei with corrected emerin or lamin B1 localization. Pictures on the right are a magnification of areas delimited with white dotted squares. (Scale bar: 50  $\mu$ m).

**Figure S6: Evaluation of *trans*-splicing efficiency *in vivo*.**

(**A**) Hematoxylin eosin staining of striated muscles sections from WT mice 50 days post-systemic injection with AAV2/9 expressing PTM-BD3. (Scale bar: 50  $\mu$ m). *TA*: *Tibialis anterior*; *Gast*: *Gastrocnemius*. (**B**) Immunofluorescence analysis of *Tibialis anterior* sections from WT mice 50 days post-systemic injection with AAV2/9-PTM-0, -PTM-BD4 and PTM-BD4inv. Cells were double-stained with anti-FLAG (green) and anti-Lamin A/C (red) antibodies. Nuclei were stained with DAPI (blue). (Scale bar: 10  $\mu$ m). (**C**) PCR analysis was performed with primers specific for *trans*-spliced *Lmna* (F-FLAG and R-*Lmna* exon 7), PTM (F-FLAG and R-*Lmna* exon 1) or total *Lmna* (F-*Lmna* exon 1 and R-*Lmna* exon 1) on RNA extracts from 15 days-old mouse heart, *Gastrocnemius* and liver after AAV2/9-PTM-BD4.

**Supplemental Table 1: Sequence of the different binding domains targeting intron 5 of *Lmna* pre-mRNA.**

<b>BD1</b>	CCCTGGAAAGCCAGACAGGCATCAGATTCAGAACCATAGCATGTGGTCCTGGAGTCCCTCCCCACCC CCTTCTCAGTGGGCTTCTGCAGTATCTGCTTAGACCAGAGCCAAGGTGGGAGGGGTAAACTGAGGGTC ACCTG
<b>BD2</b>	CATGTCCAGTCCAAGGGAAGCTCTATCTCCAAGTAGGGAATGCGGCTGGGTTTGTAACTCAGTGAGAA AGCACCTATCTACCAAGCAAGAGGCCTCTGGTTTCAGTCTCCGGCAGGCACAGAAGAAACATGAAAAAC CCTTCATGCACA
<b>BD3</b>	TCAGTGAGAAAGCACCTATCTACCAAGCAAGAGGCCTCTGGTTTCAGTCTCCGGCAGGCACAGAAGAAACATG AAAAACCCCTTCATGCACAGTAAATAGAGGCCTCTGAGGATCAGGGCTAGCTAAAGGAGAGCCCTGGAAAGCC AGACAG
<b>BD4</b>	AGTTAAGGGTGACCTTGAATCTCTGATACTCAACCTGAGATAAAAGGCATGCACCACCCAGTTCCTGTGG TCCTGGGGATAGAAGCCAGGCCATCGTGTATAATAAGCAAGCACTGTACCAACTGAGCTACATGTCCAGTCC AAGGGA
<b>BD5</b>	CTGCCTCCCGAGTGCTGGGATTAAGGCCTGTGCTATTACAACCTGGCTTCTTTTCTTTCTTTTTTGAGATA AGGTCTGGTAGTCTAGGCTGGTCTCAAACCTGCTGTATAGTTAAGGGTGACCTTGAATCTCTGATACTTCAA CCTGAG
<b>BD6</b>	TGTTTGTGTTGTGGTATTTTGGTTTGGTTTGGTTTGGTTTGGTTTGGTTTCAAGACAGGGTTTCTCTGTATAGCCCTGG CTGTCCGGAACCTCACTTTGTAGACCAGGCTGGCCTCGAACTCAGAAATCCTCCTGCCTCTGCCTCCCGAGT GCTGGG
<b>BD7</b>	CACTGCAGTGTGCATGACAGACCTGGGAGTCCCGGAGGACAAGAATGTTTCATCATTTTCCACTTTTTTTTTTA AGGATTTTTATTTATGTGTTGTTTGGTTTGGTTTGGTTTGGTTTGGTTTGGTTTGGTTTGGTTTGGTTTCA AGACAG
<b>BD8</b>	TCTGTCTGAAACCTCTCATTCCGAGGCTAGACCCCATCTTCTTTTGTACAAAATAGTGTAGCTATTGTGAC AAATAATATCGACACAAGTAACATTTCACTGCAGTGTGCATGACAGACCTGGGAGTCCCGGAGGACAAGAA TGTTCA
<b>BD9</b>	AAGGGCTGATGTCGATGAAGAGGGAGGGGCACAGGGGCAGGCAGAGGGACACTCAGGATCTGTAGGCTCTCT CTAGAGCCACCATGGCCTTATCCAGTGACCAGGAAGCCCTTCTAATGTCTGTCTGAAACCTCTCATTCCGA GGCTAG

**Supplemental Table 2: PCR primers used to amplify trans-spliced *Lmna* mRNA, total *Lmna* mRNA and PTM mRNA.**

<b>Primer</b>	<b>Sequence</b>
F-FLAG	ATGGACTACAAGGACGACGA
F- <i>Lmna</i> ex1	GCCAGCTCTACCCCACTGT
R- <i>Lmna</i> ex1	CAGACTCAGTGATGCGAAGG
F- <i>Lmna</i> ex2	GGGACTTGTTGGCTGCGCA
R- <i>Lmna</i> ex6-1	TCCAGGGCCAGCTTGATGTCCAG
R- <i>Lmna</i> ex9-2	CCATCTCTCGCTCTTTCTCA
R- <i>Lmna</i> ex7	CCGCACGAACTTTCCTCTT